Alpha Paradigm Partners’s Integra LifeSciences IART Stock Holding History

Alpha Paradigm Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$844K	Buy	+15,047	New	+$766K	0.35%	92

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alpha Paradigm Partners's IART Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Integra LifeSciences (IART) in Q4 2022: 15,047 shares worth $844K. The stake represents 0.35% of the portfolio and ranks #92 among its holdings.

281 funds tracked by Wall St. Rank hold IART as of Q4 2022.

Alpha Paradigm Partners held 15,047 shares of Integra LifeSciences worth $844K as of Q4 2022.
Integra LifeSciences was a new Alpha Paradigm Partners position in Q4 2022.
Integra LifeSciences made up 0.35% of Alpha Paradigm Partners's portfolio in Q4 2022, its #92 holding.
281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.